Anti-maternal embryonic leucine zipper kinase (Homo sapiens) Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project
(www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these
protocols and other useful information about Prestige Antibodies and the HPA, visit .
Allgemeine Beschreibung
The maternal embryonic leucine zipper kinase (MELK) is a member of the CAMK serine/threonine protein kinase superfamily. It is expressed at high level in oocytes, spermatogonia and embryos. This gene is mapped to human chromosome 9p13.
Biochem/physiol Actions
The maternal embryonic leucine zipper kinase (MELK) prevents HIV-1 (human immunodeficiency virus) replication. It participates in cell cycle, cytokinesis, mRNA splicing and apoptosis. MELK also plays an important role in the development of germ cells.
Anti-maternal embryonic leucine zipper kinase (Homo sapiens) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
